Barcelona, Spain (ots/PRNewswire) - The addition of Avastin(R) (bevacizumab, rhuMAb-VEGF) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal ...
Espoo, Finland (ots/PRNewswire) - Negotiations have been completed with the personnel representatives in Orion Diagnostica Oy, a subsidiary of Orion Corporation, concerning operational rearrangements at Orion Diagnostica's sites in Finland. As a result of the negotiations, a decision has been made to transfer the production operations of the Oulunsalo plant to Turku. There are 30 employees at the Oulunsalo site. ...
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the U.S. for Protection Against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
Vienna, Austria (ots/PRNewswire) - - Data from ADEPT study showed HUMIRA slowed progression of structural joint damage Results from Abbott's Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) show that HUMIRA(R) (adalimumab) treated both joint and skin aspects of the disease and improved the quality of life measurements in patients with moderate ...
Cordis Medizinische Apparate GmbH
Miami (ots/PRNewswire) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the CYPHER(R) and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well as several other catheter-based products. Cordis intends to file an appeal with the ...
Stockholm, Sweden (ots/PRNewswire) - Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, announced that new data from a randomised, double-blind Phase 3 study demonstrate that Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg once every three weeks is at least as effective as ...
Research Triangle Park, North Carolina (ots/PRNewswire) - Quintiles Transnational Corp. today announced that Quintiles Laboratories Asia (QLAB Asia) has amended its existing agreement with Peking Union Medical College Hospital (PUMCH) to enhance central laboratory services in China. The new amended agreement with PUMCH enhances services for customers by allowing Quintiles central laboratory (QLAB) facilities in ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The study, involving 17 healthy subjects with mild to moderate plaque psoriasis, was designed to characterize the local efficacy and safety of three concentrations of CTA018. Results ...
San Diego, California (ots/PRNewswire) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has entered into an exclusive global license and co-development agreement with Novartis to develop, ...
Cranberry Township, Pennsylvania (ots/PRNewswire) - Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal ...
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
Los Angeles (ots/PRNewswire) - Infotrieve, Inc. announced today the immediate availability of the company's Life Science Research Center(TM) (LSRC), a web-based information research tool that provides scientists with one-stop search access to critical information that impacts scientific workflow. The LSRC was designed to simplify research by eliminating the need for logins to multiple information sources including ...
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show ...
Orlando, Florida (ots/PRNewswire) - Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Népszabadság, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima, have been named today by The European School of Oncology (ESO) as joint winners of the ACE (Awarding ...
Orlando, Florida (ots/PRNewswire) - - New Results Presented at ASCO Results from five clinical studies of YONDELIS (TM) (trabectedin) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Florida, from 13-17 May 2005. YONDELIS is being developed by PharmaMar ...
Basel, Switzerland (ots/PRNewswire) - The addition of Tarceva(tm) (erlotinib) to chemotherapy extends survival by 23.5% for patients with advanced pancreatic cancer, according to data presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA.(1) Tarceva, an advanced new cancer drug taken as a once-daily tablet, has already demonstrated a clear survival benefit for patients with ...
Basel, Switzerland (ots/PRNewswire) - - Anti-Angiogenic Treatment Shows Survival Benefit Across Three Major Cancer Types: Breast, Lung And Colorectal Cancer A new study with Avastin(R) (bevacizumab, rhuMAb-VEGF) today reported that when used in combination with chemotherapy, Avastin doubled the chances of ...
Basel, Switzerland (ots/PRNewswire) - - Addition of Avastin Boosts Efficacy of First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer A new study, presented for the first time today, reveals that Avastin(R) (bevacizumab rhuMAb-VEGF) significantly extends survival for patients with previously untreated, advanced non-small cell lung cancer (NSCLC), ...
Milan, Italy (ots/PRNewswire) - - Net Revenues Grow to 179.3 Million Euros in the First Quarter of 2005, or 1.8% More Than in the Same Period Last Year.(1) - EBITDA Total 16.5 Million Euros, Compared With 18.2 Million Euros in 2004, Improving 5.1% vs. Same Period Last Year (net of Exceptional Items of 2.5 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. The planned randomized, open-label trial will include approximately 332 de novo (newly ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences, Inc., a Montreal-based gene and drug target discovery company, announced today it has acquired the majority of the assets and staff of Sweden-based Global Genomics AB. Through this transaction, Genizon has gained access to a novel sequencing technology, ...
Espoo, Finland (ots/PRNewswire) - Net sales of the Orion Group were EUR 465.3 (496.9) million, down by 6.4% due to decreased invoicing of the pharmaceutical distribution business. Group operating profit grew by 52.2% to EUR 50.8 (33.4) million, thanks to the favourable performance of Orion Pharma. Group profit before taxes was EUR 50.6 (33.0) million. Earnings per share were EUR 0.27 (0.17). Equity ratio was 40.7% ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company will web cast its Annual General Meeting in Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall Yatscoff, President and COO presenting the scientific update. Interested parties can ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. announced today that the Company has received the first tranche of a CDN $15 million financing. The funds will be used by Cytochroma to continue advancement of CTA018 towards a Phase II clinical trial for psoriasis as well as to extend its pipeline of late-stage preclinical products. This recent round of financing was led by VenGrowth Private Equity Partners Inc. ...
Amsterdam, Netherlands (ots/PRNewswire) - - Hospira Healthcare B.V. will also serve as regional headquarters for Europe, Middle East and Africa -- Today Hospira, Inc. (pronounced Hos-PEER-ah), a global independent specialty pharmaceutical and medication delivery company created in April 2004 from the core global hospital products business of Abbott Laboratories, announced that it has established its presence ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. This randomized, open-label trial will include approximately 332 de novo (newly transplanted) kidney patients. Patients ...
Madrid (ots/PRNewswire) - PharmaMar: - Zalypsis: this is PharmaMar's fifth compound to reach clinical development. - Aplidin: commenced Phase II studies on prostate and bladder cancer. - Yondelis: pivotal Phase III studies commenced on ovarian cancer patients. NeuroPharma: - Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease. Other: - ...